In a Phase 2b clinical trial, oral povorcitinib showed promise at week 52 for treating extensive nonsegmental vitiligo.

Published Date: 27 Oct 2023

USA: Significant total body and facial vitiligo was linked to oral povorcitinib treatment in adult patients with extensive nonsegmental vitiligo.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot